Akamis Bio

Akamis Bio is a clinical-stage oncology company developing oncolytic adenoviral therapeutics for solid tumours.

Its platform delivers immunotherapeutic payloads directly to tumour sites following intravenous dosing, enabling tumour-localised expression of proteins including CD40 agonist antibodies and cytokines.

Lead programme NG-350A is in a Phase 1b trial for locally advanced rectal cancer, having received FDA Fast Track Designation; NG-641 is in Phase 1 combination studies in advanced epithelial tumours.